Wells Fargo & Company Tarsus Pharmaceuticals, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TARS
# of Institutions
170Shares Held
43.3MCall Options Held
484KPut Options Held
4.1K-
Rtw Investments, LP New York, NY3.41MShares$165 Million1.79% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$158 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.44MShares$118 Million2.89% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$109 Million6.32% of portfolio
-
Morgan Stanley New York, NY2.21MShares$107 Million0.01% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.29B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...